ArticleBMC cancer2025
The predicting role of albumin to derived neutrophil-to-lymphocyte ratio for the prognosis of esophageal squamous cell carcinoma patients aged 60 years and above.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the clinical significance of albumin(Alb) to the derive(d) neutrophil-to-lymphocyte ratio(NLR) in patients with esophageal squamous cell carcinoma (ESCC) aged 60 years and above.
methods328 patients with ESCC at Shanxi Province Cancer Hospital were enrolled in this study. The dNLR was calculated using the following formula: neutrophil count / (leukocyte count - neutrophil count). Alb to dNLR or the Alb/dNLR ratio was calculated by dividing the Alb level by the dNLR level.Receiver operating characteristic (ROC) curve analysis was used to determine the cutoff values for Alb to dNLR.
resultsROC analysis displayed that the cut-off value of Alb to dNLR was defined to be 20.28 U/mL. The AlbtodNLR was not related to clinical features but to survival status (all P > 0.05). ESCC patients aged 60 years and above with a high AlbtodNLR had better survival than those with a low Alb-to-dNLR (P = 0.005). Similar results were observed in male patients with ESCC (P = 0.001), subgroups with upper and middle locations (P = 0.013 and 0.017), tobacco consumption (P = 0.004), non-drinkers (P = 0.029), well and moderate differentiation (P = 0.014), lymph node involvement (P < 0.001), advanced T stage (P = 0.014), and advanced TNM staging (P = 0.001). Univariate Cox regression analysis indicated that tumor grade, T staging, lymph node metastasis(LNM), TNM staging, and Alb to dNLR ratio were predictors of death from ESCC. In a multivariate Cox regression analysis, a lower AlbtodNLR levels, and advanced T stage were associated with an increased risk of ESCC-related death.
conclusionsCollectively, Alb to dNLR were inversely associated with outcome and were regarded as an independent influencing factor for ESCC subpopulation aged 60 years and above.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.